Related references
Note: Only part of the references are listed.Neutrophil Extracellular Traps Tied to Rheumatoid Arthritis: Points to Ponder
Wenpeng Song et al.
FRONTIERS IN IMMUNOLOGY (2021)
Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
Marta Palomo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Defibrotide Modulates Pulmonary Endothelial Cell Activation and Protects Against Lung Inflammation in Pre-Clinical Models of LPS-Induced Lung Injury and Idiopathic Pneumonia Syndrome.
Orly R. Klein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management
Deepika S. Darbari et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease
David Garcia-Bernal et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
p38 MAPK inhibition: A promising therapeutic approach for COVID-19
Joseph M. Grimes et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2020)
Response to Maccio et al, Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?
Edward Richardson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Blood-Brain Barrier in Cerebral Malaria: Pathogenesis and Therapeutic Intervention
Gopala Nishanth et al.
TRENDS IN PARASITOLOGY (2019)
Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide
Julia Martinez-Sanchez et al.
FRONTIERS IN IMMUNOLOGY (2019)
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome
Nancy A. Kernan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications
Uri Barash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications
Uri Barash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada
Jonathan Belsey et al.
BLOOD (2018)
The use of defibrotide in blood and marrow transplantation
Paul G. Richardson et al.
BLOOD ADVANCES (2018)
DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis
Nirit Mor-Vaknin et al.
NATURE COMMUNICATIONS (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation
L. Yeates et al.
BONE MARROW TRANSPLANTATION (2017)
Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment
Jean-Hugues Dalle et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
Paul G. Richardson et al.
BLOOD (2016)
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance
Marta Palomo et al.
BLOOD (2016)
Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?
Emre Tekgunduz et al.
TRANSFUSION AND APHERESIS SCIENCE (2016)
Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
Kazuo Umemura et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
M. Mohty et al.
BONE MARROW TRANSPLANTATION (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease)
Cathy Q. Fan et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2014)
Defibrotide: Properties and clinical use of an old/new drug
R. Pescador et al.
VASCULAR PHARMACOLOGY (2013)
Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria
Ivo M. B. Francischetti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
Selim Corbacioglu et al.
LANCET (2012)
Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation
Marta Palomo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
The role of the endothelium in the short-term complications of hematopoietic SCT
E. Carreras et al.
BONE MARROW TRANSPLANTATION (2011)
Histone deacetylases as regulators of inflammation and immunity
Melanie R. Shakespear et al.
TRENDS IN IMMUNOLOGY (2011)
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial
Paul G. Richardson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors
Olga Ostrovsky et al.
BLOOD (2010)
Histone Deacetylase 3 Is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow
Anna Zampetaki et al.
CIRCULATION (2010)
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity
Cinara L. Echart et al.
BLOOD COAGULATION & FIBRINOLYSIS (2009)
Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
Constantine S. Mitsiades et al.
CLINICAL CANCER RESEARCH (2009)
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease
Luba Benimetskaya et al.
BLOOD (2008)
An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo
Gudrun E. Koehl et al.
CANCER BIOLOGY & THERAPY (2007)
Expression and function of laminins in the embryonic and mature vasculature
R Hallmann et al.
PHYSIOLOGICAL REVIEWS (2005)
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells
A Falanga et al.
LEUKEMIA (2003)
Veno-occlusive disease: cytokines, genetics, and haemostasis
JA Coppell et al.
BLOOD REVIEWS (2003)
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
PG Richardson et al.
BLOOD (2002)
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide
G Eissner et al.
BLOOD (2002)
Tissue factor pathway inhibitor release induced by defibrotide and heparins
G Cella et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2001)
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
SL Friedman
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
